Bibliography
- Lane NE. Epidemiology, etiology, and diagnosis of osteoporosis. Am J Obstet Gynecol 2006;194:S3-11
- McCombs JS, Thiebaud B, McLaughlin-Miley C, Shi J. Compliance with drugs therapies for the treatment and prevention of osteoporosis. Maturitas 2004;48:271-87
- Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2007;346:653-61
- Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809-22
- Lyles KW, Colón-Emetic CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357:1799-809
- Colón-Emetic C, Kuchibhatia M, Pieper C, et al. The contribution of hip fracture to risk of subsequent fractures: data from two longitudinal studies. Osteoporos Int 2003;4:879-83
- Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1 – 34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
- Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1 – 84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis – a randomized trial. Arch Intern Med 2007;146:326-39
- McClung MR, Lewecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;358:821-31
- Osteoporosis. Available at: http://osteoporosisblogger.com/category/medications/rankl-antagonist/denosumab-amg-162/